Prestige Consumer Healthcare Inc.

PBH

US74112D1019

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:03 2024-06-21 pm EDT			5-day change	1st Jan Change
69.4 ^USD	+6.31%		+8.02%	+13.36%

Jun. 21	DA Davidson Upgrades Prestige Consumer Healthcare to Buy From Neutral, Adjusts Price Target to $93 From $65	MT
May. 15	Sector Update: Health Care Stocks Rise Pre-Bell Wednesday	MT

Prestige Consumer Healthcare Inc. Reaffirms Earnings Guidance for the Fiscal Year 2023

November 03, 2022 at 06:00 am EDT

Prestige Consumer Healthcare Inc. reaffirmed earnings guidance for the fiscal year 2023. For the year, the company expects revenue to be in the range of $1,120 to 1,130 million and diluted EPS to be in the range of $4.18 to $4.23.

Latest news about Prestige Consumer Healthcare Inc.

DA Davidson Upgrades Prestige Consumer Healthcare to Buy From Neutral, Adjusts Price Target to $93 From $65	Jun. 21	MT
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday	May. 15	MT
Transcript : Prestige Consumer Healthcare Inc., Q4 2024 Earnings Call, May 15, 2024	May. 15
North American Morning Briefing : Traders Brace for CPI Inflation Data	May. 15	DJ
Prestige Consumer Healthcare Shares Fall Pre-Bell After Fiscal Q4 Miss	May. 15	MT
Prestige Consumer Healthcare Fiscal Q4 Adjusted Earnings, Revenue Drop; Fiscal 2025 Outlook Set; Shares Fall After Hours	May. 14	MT
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Reports Q4 Revenue $277M, vs. Street Est of $287.4M	May. 14	MT
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Posts Q4 EPS $1.02, vs. Street Est of $1.14	May. 14	MT
Prestige Consumer Healthcare Inc. announces an Equity Buyback for $300 million worth of its shares.	May. 14	CI
Prestige Consumer Healthcare Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 14	CI
Prestige Consumer Healthcare Inc. Provides Earnings Guidance for the Fiscal Year 2025	May. 14	CI
Prestige Consumer Healthcare Inc. authorizes a Buyback Plan.	May. 13	CI
Prestige Consumer Healthcare Inc. Appoints John F. Kelly to Board of Directors	May. 08	CI
Prestige Consumer Healthcare Insider Sold Shares Worth $1,766,665, According to a Recent SEC Filing	Feb. 16	MT
Prestige Consumer Healthcare Insider Sold Shares Worth $2,051,874, According to a Recent SEC Filing	Feb. 16	MT
Prestige Consumer Healthcare Insider Sold Shares Worth $368,184, According to a Recent SEC Filing	Feb. 12	MT
Prestige Consumer Healthcare's Fiscal Q3 Earnings, Revenue Increase; Raises 2024 Earnings Guidance; Shares Gain	Feb. 08	MT
Transcript : Prestige Consumer Healthcare Inc., Q3 2024 Earnings Call, Feb 08, 2024	Feb. 08
North American Morning Briefing : S&P 500 to Open -2-	Feb. 08	DJ
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Reports Q3 Revenue $282.7M, vs. Street Est of $280.4M	Feb. 08	MT
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Reports Q3 EPS $1.06, vs. Street Est of $1.04	Feb. 08	MT
Prestige Consumer Healthcare Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
Prestige Consumer Healthcare Inc. Revises Earnings Guidance for the Year of Fiscal 2024	Feb. 08	CI
Prestige Consumer Healthcare Unit Recalls 2 Lots of Ting Antifungal Spray Liquid on High Levels of Benzene	Feb. 02	MT
Prestige Consumer Healthcare Unit Recalls One Lot of Anesthetic Spray Due to Benzene Presence	Dec. 22	MT

Chart Prestige Consumer Healthcare Inc.

Duration

Period

More charts

Company Profile

Prestige Consumer Healthcare Inc. is consumer healthcare products company. The Company is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club and e-commerce stores in North America (the United States and Canada) and in Australia and certain other international markets. It operates through two segments: North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summerâs Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreauxâs Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.

Sector

Pharmaceuticals

Calendar

2024-07-31 - Q1 2025 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Prestige Consumer Healthcare Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

69.4 USD

Average target price

78.17 USD

Spread / Average Target

+12.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PRESTIGE CONSUMER HEALTHCARE INC.	+13.36%	3.46B
ELI LILLY AND COMPANY	+51.63%	796B
NOVO NORDISK A/S	+41.51%	628B
JOHNSON & JOHNSON	-5.10%	358B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+9.95%	301B
ASTRAZENECA PLC	+17.66%	244B
ROCHE HOLDING AG	+3.39%	228B
NOVARTIS AG	+10.75%	214B
AMGEN INC.	+6.99%	165B

Other Pharmaceuticals